Journal of Fertility Biomarkers invites high quality submissions that advance biomarker discovery, validation, and clinical translation in reproductive medicine. We welcome original research, systematic reviews, clinical trials, and translational studies that improve fertility assessment and treatment outcomes.

Our editorial focus prioritizes rigorous assay validation, transparent reporting, and actionable insights for clinical fertility care.

• Ovarian reserve biomarkers (AMH, FSH, AFC) and reproductive aging
• Male factor biomarkers including semen analysis and DNA fragmentation
• Endometrial receptivity and implantation biomarkers
• Embryo viability and selection biomarkers, including morphokinetics
• Noninvasive biomarkers from follicular fluid or spent media
• Proteomics, metabolomics, genomics, and multi omics approaches
• Inflammatory, immune, and microbiome biomarkers in fertility care
• Biomarkers for PCOS, endometriosis, and unexplained infertility
• Fertility preservation and oncofertility biomarker studies
• Predictive models for ART response and treatment personalization
• Biomarkers for ovarian stimulation and luteal phase support
• Clinical outcomes including implantation, pregnancy, and live birth

• Clinical cohort studies with defined outcomes
• Protocol papers for assay validation and biomarker reproducibility
• Data resource reports that enable reuse or benchmarking
• Technical notes on laboratory or imaging methods

Successful submissions present a clear clinical question, robust assay methodology, and transparent reporting of outcomes. We value studies that connect biomarker signals to clinical decision making in fertility care.

Authors should document sample timing, assay validation, and outcome definitions to support reproducibility and clinical relevance.

• Clear inclusion and exclusion criteria with diagnosis detail
• Validated biomarkers or imaging criteria
• Appropriate statistical analysis and confounder control
• Interpretation aligned with clinical practice implications

Submissions undergo editorial screening for scope fit, methodological rigor, and reporting completeness. Qualified manuscripts move to single blind peer review with subject matter experts.

JFB operates under an open access model to ensure fertility biomarker evidence is discoverable and reusable. APCs are applied after acceptance and support peer review, production, and archiving services.

Membership options and affordable APC waivers are available for eligible authors. Contact the editorial office at [email protected] for guidance.

• Scope fit confirmed for fertility biomarkers
• Assay validation and sample timing reported
• Data availability statement included
• Ethics approvals and patient consent described
• Cover letter explains novelty and clinical impact
• Define the primary biomarker category (hormonal, imaging, genomic, proteomic, or metabolomic).
• Report assay platform, manufacturer, and kit lot numbers where applicable.
• Provide sample collection timing relative to cycle day or stimulation phase.
• Describe specimen type and handling conditions (serum, plasma, follicular fluid, semen).
• Include storage temperature, freeze thaw cycles, and transport timelines.
• Provide calibration procedures and quality control ranges.
• Report intra assay and inter assay variability.
• Specify detection limits and linearity ranges for biomarker assays.
• Use standardized units and reference ranges for all biomarkers.
• Define cohort inclusion and exclusion criteria in detail.
• Report infertility diagnosis categories (PCOS, endometriosis, male factor, unexplained).
• Describe ovarian reserve markers measured (AMH, FSH, AFC).
• Provide ultrasound methodology and counting criteria for AFC.
• Report hormonal assay timing (follicular, luteal, trigger day).
• Describe stimulation protocol details and medications.
• Provide number of oocytes retrieved and maturity rates.
• Report fertilization method (IVF or ICSI).
• Provide embryo grading criteria and day of assessment.
• Include morphokinetic parameters if time lapse imaging is used.
• Report PGT methods and indications when relevant.
• Describe endometrial assessment method and timing.
• Define implantation, clinical pregnancy, and live birth outcomes.
• Report miscarriage and obstetric outcome definitions.
• Include male factor biomarker measures (DNA fragmentation, ROS, motility).
• Provide semen analysis standards and WHO reference criteria.
• Report abstinence period for semen samples.
• Describe laboratory equipment and imaging settings.
• Provide statistical power and sample size justification.
• Adjust for confounders such as age, BMI, and smoking.
• Report handling of repeated cycles per patient.
• Describe blinding and randomization when applicable.
• Provide missing data handling and sensitivity analyses.
• Include external validation or replication cohorts.
• Provide model performance metrics for predictive tools.
• Report calibration and discrimination metrics for models.
• Describe feature selection and preprocessing steps for omics data.
• Provide batch effect correction methods for omics datasets.
• State ethics approvals and consent procedures.
• Provide data availability statements and repository links.
• Describe clinical decision thresholds for biomarker adoption.
• Report cost or resource implications when relevant.
• Include patient reported outcomes when collected.
• Describe geographic and demographic diversity of the cohort.
• Report laboratory accreditation status when applicable.
• Provide assay cross reactivity information.
• Describe quality assurance procedures in the lab.
• Report time from sample collection to analysis.
• Include details on environmental or lifestyle covariates.
• Describe ovarian stimulation response metrics.
• Report luteal phase support regimens when applicable.
• Include details on cryopreservation methods.
• Report embryo transfer protocols (fresh vs frozen).
• Provide endometrial thickness measurement technique.
• Describe imaging interpretation criteria for biomarkers.
• Report follow up duration for outcomes.

JFB is committed to rigorous, transparent publishing in fertility biomarker research and reproductive medicine. We emphasize reproducible laboratory methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in biomarker validation, reproductive outcomes, and translational fertility science.